“As a policy we don’t want to comment on speculative news,” said Sudhir Mehta, chairman emeritus of Torrent Pharma, referring to reports about the race to acquire Cipla at the company’s earnings call. Mehta said the company’s capital allocation will be largely geared towards India.
